La Jolla Labs Celebrates Advancing RNA Therapies for Patients as It Nears Five Years

La Jolla Labs has announced that it is approaching five years of work dedicated to advancing equitable access to precision ribonucleic acid (RNA) therapeutics. The company contributes to RNA discovery and provides translational support for families affected by rare conditions. Its early commitment to assisting clinicians and researchers in rare pediatric disorders continues to inform the design and evaluation of RNA therapies, with an emphasis on care and accessibility. This year, the company has delivered over 20 drugs to treat patients with rare diseases...